Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines

The CDKN2A tumor‐suppressor locus on chromosome band 9p21, which encodes p16INK4A, a negative regulator of cyclin‐dependent kinases, and p14ARF1, an activator of TP53, is inactivated in many human cancers by point mutation, promoter hypermethylation, and, often, deletion. Homozygous deletions are unusually prevalent at this locus in very different human cancers. In the present study, we compared deletions in squamous cell carcinoma of the head and neck (SCCHN) cell lines to those in T‐cell acute lymphatic leukemia (T‐ALL), glioma, and bladder carcinoma (TCC) cell lines. Of 14 SCCHN lines, 10 showed homozygous deletions of CDKN2A, one displayed promoter hypermethylation with gene silencing, and one had a frameshift deletion in exon 2. Many deletion ends were in or proximal to the repetitive sequence clusters flanking the locus. Breakpoint junctions displayed variable microhomologies or insertions characteristic of DNA repair by nonhomologous end‐joining. In general, deletions were much smaller in SCCHN than in TCC and glioma. In T‐ALL, breakpoints were near consensus sites for recombination mediated by RAG (recombination activating genes) enzymes, and the structure of the junctions was consistent with this mechanism. We suggest that different mechanisms of CDKN2A deletion prevail in different human cancers. Aberrant RAG‐mediated recombination may be responsible in T‐ALL, and exuberant DNA repair by nonhomologous end‐joining is the likely prevailing mechanism in SCCHN, but a distinct mechanism in TCC and glioma remains to be elucidated. © 2004 Wiley‐Liss, Inc.

[1]  G. Reifenberger,et al.  Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. , 2004, Journal of the National Cancer Institute.

[2]  W. Schulz,et al.  Inactivation of tumor suppressor genes and deregulation of the c-myc gene in urothelial cancer cell lines , 2004, Urological Research.

[3]  Jun Yokota,et al.  Molecular processes of chromosome 9p21 deletions in human cancers , 2003, Oncogene.

[4]  W. Schulz,et al.  Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells , 2003, Genes, chromosomes & cancer.

[5]  D. Gisselsson.  Chromosome instability in cancer: how, when, and why? , 2003, Advances in cancer research.

[6]  Kaoru Inoue,et al.  Prevalent Involvement of Illegitimate V(D)J Recombination in Chromosome 9p21 Deletions in Lymphoid Leukemia* , 2002, The Journal of Biological Chemistry.

[7]  Peter A. Jones,et al.  Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. , 2002, Cancer research.

[8]  T. Efferth,et al.  Genomic imbalances in T-cell acute lymphoblastic leukemia cell lines. , 2002, International journal of oncology.

[9]  T. Carey,et al.  Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region , 2002, Head & neck.

[10]  R. Schiestl,et al.  Lack of WRN results in extensive deletion at nonhomologous joining ends. , 2002, Cancer research.

[11]  D. Beer,et al.  Molecular characterization of FRAXB and comparative common fragile site instability in cancer cells , 2002, Genes, chromosomes & cancer.

[12]  Jeremy M. Stark,et al.  Double-strand breaks and tumorigenesis. , 2001, Trends in cell biology.

[13]  W. Schulz,et al.  DNA Methylation and the Mechanisms of CDKN2A Inactivation in Transitional Cell Carcinoma of the Urinary Bladder , 2000, Laboratory Investigation.

[14]  W. Goedecke,et al.  Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations. , 2000, Mutagenesis.

[15]  Knowles,et al.  The genetics of transitional cell carcinoma: progress and potential clinical application , 1999, BJU international.

[16]  C. Croce,et al.  Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Read,et al.  DNA studies underestimate the major role of CDKN2A inactivation in oral and oropharyngeal squamous cell carcinomas , 1999, Genes, chromosomes & cancer.

[18]  C. Weghorst,et al.  p16 mutation frequency and clinical correlation in head and neck cancer. , 1999, Acta oto-laryngologica.

[19]  G. Peters,et al.  The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.

[20]  W. Schulz,et al.  Expression of G1→S Transition Regulatory Molecules in Human Urothelial Cancer , 1998, Japanese journal of cancer research : Gann.

[21]  A. El‐Naggar,et al.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. , 1997, The American journal of pathology.

[22]  F. Sigaux,et al.  Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. , 1997, Blood.

[23]  D. Papadopoulo,et al.  The fidelity of double strand breaks processing is impaired in complementation groups B and D of fanconi anemia, a genetic instability syndrome , 1997, Somatic cell and molecular genetics.

[24]  C. Walsh,et al.  Cytosine methylation and the ecology of intragenomic parasites. , 1997, Trends in genetics : TIG.

[25]  M. Berger,et al.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. , 1996, Cancer research.

[26]  O. Olopade,et al.  Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines , 1994, Molecular and cellular biology.

[27]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.